학술논문

Immunophenotypic Markers and Antiretroviral Therapy (IMART): T Cell Activation and Maturation Help Predict Treatment Response.
Document Type
Article
Source
Journal of Infectious Diseases. 5/15/2004, Vol. 189 Issue 10, p1811-1820. 10p.
Subject
*AIDS
*HIV
*HIV infections
*THERAPEUTICS
*MEDICAL research
*MEDICAL experimentation on humans
Language
ISSN
0022-1899
Abstract
To determine whether markers of T cell activation and maturation are independently predictive of the response to potent antiretroviral therapy, the Immunophenotypic Markers and Antiretroviral Therapy study applied a novel data-sharing strategy across 5 Adult AIDS Clinical Trial Group trials that counted naive and activated CD4+ and CD8+ T cells in 324 subjects. Regression models-adjustment for baseline CD4 cell count, human immunodeficiency virus (HIV) RNA, and study-revealed that high pretreatment CD8+ T cell activation predicted virologic failure (P = .046). Additional models showed the greatest increase in CD4+ T cell counts in subjects with highest pretreatment naive CD4+ T cell counts (P< .0001), which was enhanced by high CD4+ and low CD8+ T cell activation. Total lymphocyte count also predicted a subsequent CD4+ T cell change. These results document the utility of T cell markers in predicting treatment outcome and their potential value for the study and management of HIV-1 infection. [ABSTRACT FROM AUTHOR]